{
  "docId": "019de516-01ce-701d-bd9b-acac15fa9fab",
  "docSlug": "a13be9775a99db49a0c5c2ac3ee2ea88",
  "documentTitle": "Oculis | Investor Conference Presentation Deck | 39 slides",
  "authorId": "oculis",
  "authorName": "Oculis",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 21,
  "pageCount": 39,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "kpi_overview",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de516-01ce-701d-bd9b-acac15fa9fab/21",
  "deckHref": "/decks/019de516-01ce-701d-bd9b-acac15fa9fab",
  "deckJsonHref": "/decks/019de516-01ce-701d-bd9b-acac15fa9fab.json",
  "deckAnchorHref": "/decks/019de516-01ce-701d-bd9b-acac15fa9fab#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.039,
        "w": 0.109,
        "x": 0.85,
        "y": 0.04
      },
      "kind": "image",
      "text": "Oculis",
      "attrs": {},
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "79e0a51c-1a2e-40c4-9be3-b52fe2746951",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.11,
        "w": 0.91,
        "x": 0.04,
        "y": 0.18
      },
      "kind": "list",
      "text": "Trial Objectives Met\nResults validated loading and maintenance regimen to optimize OCS-01 efficacy potential in DME with robust statistical significance",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6342f7c9-38ca-413f-b038-559dbbd7880f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.91,
        "x": 0.04,
        "y": 0.57
      },
      "kind": "list",
      "text": "Safety\nNo unexpected safety findings observed",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "94e6e02d-ff05-4801-878c-7c93f67d1872",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.24,
        "w": 0.91,
        "x": 0.04,
        "y": 0.32
      },
      "kind": "list",
      "text": "Functional & Clinical Benefits\nOCS-01 met all functional and clinical benefit endpoints in a robust, statistically superior manner (in 3-month trial):\nImprovement of visual acuity (Functional Endpoint)\nIncrease in proportion of patients with a 3-line or greater gain (Clinical Benefit Endpoint)\nReduction in macular edema as measured by OCT imaging (Pharmacodynamic Endpoint)",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c7c5fa0e-450b-421d-b35e-0295d991583b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.77,
        "x": 0.11,
        "y": 0.79
      },
      "kind": "paragraph",
      "text": "Next Step: Commence Stage 2 of Phase 3 program to support NDA filing of OCS-01 for DME treatment",
      "attrs": {},
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "106ff4c7-939e-4390-b383-dcb46131a522",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.016,
        "w": 0.019,
        "x": 0.936,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "21",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c4cd09aa-7715-48a1-8d2f-57564384033f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.75,
        "x": 0.029,
        "y": 0.049
      },
      "kind": "title",
      "text": "Postive OCS-01 Ph 3 Stage 1 Results Derisking Stage 2 Trial",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4fae9420-cc60-48e8-a59f-84e9364d8865",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 24,
      "from": 17,
      "beatId": "47165210-81f8-47ad-ae3f-2582e7380461",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Solution & Approach",
      "beatSlug": "consultants-gambit-solution-approach",
      "evidence": "Slides 17-24 outline OCS-01's potential and the Phase 3 program.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}